Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(35 sites)
United States
HonorHealth Research Institute, Scottsdale, Arizona Precision NextGen Oncology and Research, Beverly Hills, California City of Hope, Duarte, California Valkyrie Clinical Trials, Los Angeles, California University of California, San Diego (UCSD) - Moores Cancer Center, San Diego, California University of California, San Francisco (UCSF), San Francisco, California Sarcoma Oncology Center, Santa Monica, California University of Colorado Hospital, Aurora, Colorado Emory University - Winship Cancer Institute, Atlanta, Georgia The University of Chicago, Chicago, Illinois University of Michigan, Ann Arbor, Michigan START Midwest Michigan, PC, Grand Rapids, Michigan David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York Cleveland Clinic, Cleveland, Ohio Oregon Health & Science University, Portland, Oregon Children's Hospital of Philadelphia- Center for Childhood Cancer Research, Philadelphia, Pennsylvania University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania Vanderbilt University School of Medicine, Nashville, Tennessee UT MD Anderson Cancer Center, Houston, Texas NEXT Oncology, San Antonio, Texas University of Virginia, Charlottesville, Virginia NEXT Oncology - Virginia, Fairfax, Virginia France
Gustave Roussy, Villejuif Italy
La Fondazione e l'Istituto di Candiolo, Candiolo Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Netherlands
University Medical Center Groningen, Groningen Academisch Ziekenhuis Leiden, Leiden Spain
Hospital Universitario Vall d'Hebron, Barcelona Hospital de la Santa Creu i Sant Pau, Barcelona Hospital Clinico San Carlos, Madrid United Kingdom
Great North Children's Hospital, London University College London Hospital, London The Royal Marsden NHS Foundation Trust, London Royal Manchester Children's Hospital, Manchester